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background: Apart from the two landmark studies which led to the approval of prasugrel and ticagrelor, bleeding incidences have not been 
reported to date. We aim to determine the incidence of clinically-significant bleeding in local Asians and to identify the possible risk factors 
for bleeding.
methods: Post-PCI patients taking prasugrel or ticagrelor between October 2011 and September 2013 were reviewed. The patients were 
followed up for a maximum of six months. Bleeding events were classified using the Thrombolysis in Myocardial Infarction (TIMI) and 
Bleeding Academic Research Consortium (BARC) definitions. Associated risk factors for bleeding were evaluated. Clinical outcomes such 
as all-cause mortality, myocardial infarction and repeat revascularization were also recorded.
Results:   Data from 304 patients (prasugrel, n = 119; ticagrelor, n = 185) was accessed. Baseline demographics include: Median age 
53/54yo, 84.0%/90.8% males, median body weight 70/68kg, complete gastroprotection 78.2%/70.3% for prasugrel/ticagrelor populations 
respectively. While STEMI, NTSEMI and UA were of similar proportions for prasugrel population, 74.6% received ticagrelor for STEMI. 
The cumulative incidences of clinically-significant bleeding events in patients receiving prasugrel and ticagrelor were estimated to be 
6.12% and 3.72% respectively, over six months. Multiple logistic regression model revealed female gender (OR 7.87, p=0.004), history of 
gastrointestinal diseases (OR 11.90, p = 0.001) and use of oral anticoagulants (OR, p=0.006) were associated with clinically-significant 
bleeding.
conclusion:  The six-month incidence rate of clinically-significant bleeding appeared higher than the randomized controlled trial bleeding 
rate for prasugrel but lower than that for ticagrelor. Associated risk factors were identified and must be considered when starting patients on 
more potent antiplatelets. Larger observational studies should be conducted.
